Immunic is advancing a Phase III test for vidofludimus calcium with a regulatory and clinical objective aimed at moving beyond what the company describes as multiple sclerosis’s inflammation ceiling. BIOCENTURY characterizes the program as assessing whether combining DHODH inhibition with direct neuroprotective effects can slow MS progression. The report places vidofludimus calcium into a late-stage context designed to evaluate disease-modifying potential rather than only symptomatic or short-term inflammatory outcomes. The company’s positioning also suggests a mechanistic bet that pairs immunomodulation with neuroprotection. For MS developers and investors, the timing and endpoint focus of the Phase III readout will help clarify whether the approach can translate into clinically meaningful progression slowing.